Quantumzyme Corp., a biotechnology company specializing in computational enzyme engineering, is actively addressing a Caveat Emptor designation placed on its securities by OTC Markets Group. The company has immediately initiated contact with OTC Markets to understand and resolve the underlying concerns.
CEO Naveen Kulkarni stated that the company is committed to working cooperatively and swiftly to have the Caveat Emptor status removed. To support this effort, Quantumzyme has retained legal counsel to help resolve the matter promptly.
In a separate but related development, the company strongly denies any connection to unauthorized promotional SMS text messages that mentioned Quantumzyme. The firm unequivocally states it did not authorize, endorse, or have prior knowledge of these messages and will fully cooperate with any regulatory reviews.
The Caveat Emptor designation and unauthorized promotional activity could potentially impact investor confidence and the company's market reputation. By proactively addressing these issues, Quantumzyme aims to demonstrate transparency and maintain its commitment to regulatory compliance.
The company remains focused on its core mission of delivering sustainable, enzyme-based solutions through advanced computational modeling and biocatalysis technologies. Quantumzyme will provide updates as the situation develops and continues to prioritize long-term value creation for its shareholders.
